Pharmaceutical Company Commits to Dual-Site AGC Biologics Deal Exceeding €0.5 Billion
The agreement builds on the customer’s long-term deal at a new Yokohama facility for five commercial biologics.
The agreement builds on the customer’s long-term deal at a new Yokohama facility for five commercial biologics.